Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002895
Status:
COMPLETED
Last Update Posted:
2013-12-04
First Post:
1999-11-01
Brief Title:
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Medical Research Council
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Randomised Trial in Relapsed Ovarian Cancer Early Treatment Based on CA 125 Levels Alone Vs Delayed Treatment Based On Conventional Clinical Indicators
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE It is not yet known if treatment for recurrent ovarian epithelial fallopian tube or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other indicators of disease recurrence
PURPOSE This randomized phase III trial is studying early chemotherapy based on blood levels of CA 125 alone to see how well it works compared to chemotherapy based on conventional clinical indicators in patients with recurrent ovarian epithelial fallopian tube or primary peritoneal cancer
PURPOSE This randomized phase III trial is studying early chemotherapy based on blood levels of CA 125 alone to see how well it works compared to chemotherapy based on conventional clinical indicators in patients with recurrent ovarian epithelial fallopian tube or primary peritoneal cancer
Detailed Description:
OBJECTIVES
Compare the benefit of early chemotherapy based on CA 125 level only vs chemotherapy based on conventional clinical indicators in patients with relapsed ovarian epithelial fallopian tube or primary peritoneal cancer
Compare the overall survival of patients treated with these regimens
Compare the quality of life of patients treated with these regimens
OUTLINE This is a randomized multicenter study Patients whose CA 125 levels rise to more than two times the upper limit of normal are randomized to one of two treatment arms
Arm I The clinician is informed of the initial rise in CA 125 level A confirmatory test is performed immediately Within 4 weeks of the initial CA 125 elevation patients with a second confirmed elevation receive treatment for recurrent disease according to standard local practice Patients with a normal CA 125 on the confirmatory test receive no treatment until clinically indicated
Arm II The clinician is blinded to the CA 125 results Patients undergo normal monitoring When clinically indicated patients commence treatment according to standard local practice
Quality of life is assessed at baseline at each follow-up visit and if treatment is instituted before each chemotherapy course
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 1400 patients will be accrued for this study
Compare the benefit of early chemotherapy based on CA 125 level only vs chemotherapy based on conventional clinical indicators in patients with relapsed ovarian epithelial fallopian tube or primary peritoneal cancer
Compare the overall survival of patients treated with these regimens
Compare the quality of life of patients treated with these regimens
OUTLINE This is a randomized multicenter study Patients whose CA 125 levels rise to more than two times the upper limit of normal are randomized to one of two treatment arms
Arm I The clinician is informed of the initial rise in CA 125 level A confirmatory test is performed immediately Within 4 weeks of the initial CA 125 elevation patients with a second confirmed elevation receive treatment for recurrent disease according to standard local practice Patients with a normal CA 125 on the confirmatory test receive no treatment until clinically indicated
Arm II The clinician is blinded to the CA 125 results Patients undergo normal monitoring When clinically indicated patients commence treatment according to standard local practice
Quality of life is assessed at baseline at each follow-up visit and if treatment is instituted before each chemotherapy course
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 1400 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ISRCTN87786644 | None | None | None |
| MRC-OV05 | None | None | None |
| EORTC-55955 | None | None | None |